[go: up one dir, main page]

MX2009004461A - Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada. - Google Patents

Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada.

Info

Publication number
MX2009004461A
MX2009004461A MX2009004461A MX2009004461A MX2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A MX 2009004461 A MX2009004461 A MX 2009004461A
Authority
MX
Mexico
Prior art keywords
bioavailability
improved stability
palonosetron hydrochloride
soft capsules
dosage forms
Prior art date
Application number
MX2009004461A
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Riccardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009004461(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MX2009004461A publication Critical patent/MX2009004461A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Siempre que sean formas de dosificación orales sólidas del clorhidrato de palonosetron, los métodos para usar las formas de dosificación para tratar el vómito, y los métodos para hacer los formas de dosificación. Los formas de dosificación han mejorado la estabilidad y biodisponibilidad, y están preferiblemente bajo la forma de cápsulas rellenas de líquido.
MX2009004461A 2006-10-24 2007-10-19 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada. MX2009004461A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24
PCT/EP2007/009098 WO2008049552A1 (en) 2006-10-24 2007-10-19 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability

Publications (1)

Publication Number Publication Date
MX2009004461A true MX2009004461A (es) 2009-09-16

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004461A MX2009004461A (es) 2006-10-24 2007-10-19 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada.

Country Status (35)

Country Link
US (2) US20080152704A1 (es)
EP (1) EP1940366B9 (es)
JP (1) JP5144527B2 (es)
KR (1) KR101441459B1 (es)
CN (1) CN101573106B (es)
AR (1) AR063362A1 (es)
AT (1) ATE427742T1 (es)
AU (1) AU2007308378B2 (es)
BR (1) BRPI0718497B1 (es)
CA (1) CA2666512C (es)
CL (1) CL2007003055A1 (es)
CO (1) CO6160289A2 (es)
CR (1) CR10728A (es)
CY (1) CY1109914T1 (es)
DE (1) DE602007000856D1 (es)
DK (1) DK1940366T3 (es)
EA (1) EA016455B1 (es)
ES (1) ES2325339T3 (es)
GT (1) GT200900096A (es)
HN (1) HN2009000785A (es)
HR (1) HRP20090341T1 (es)
IL (1) IL198225A (es)
ME (1) ME01949B (es)
MX (1) MX2009004461A (es)
NO (1) NO342353B1 (es)
NZ (1) NZ576237A (es)
PL (1) PL1940366T3 (es)
PT (1) PT1940366E (es)
RS (1) RS50842B (es)
SI (1) SI1940366T1 (es)
SV (1) SV2009003238A (es)
TW (1) TWI367212B (es)
UA (1) UA97653C2 (es)
WO (1) WO2008049552A1 (es)
ZA (1) ZA200902773B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2387994A1 (en) * 2006-01-27 2011-11-23 Eurand, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
ES2550035T3 (es) * 2006-01-27 2015-11-04 Adare Pharmaceuticals, Inc. Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
US20100143461A1 (en) * 2008-12-08 2010-06-10 Ben-Zion Solomon Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
WO2011058427A1 (en) 2009-11-13 2011-05-19 Helsinn Healthcare S.A. Palonosetron metabolites
RS53491B1 (sr) 2009-11-18 2015-02-27 Helsinn Healthcare Sa Kompozicije za lečenje centralno posredovane mučnine i povraćanja
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2744497B1 (en) 2011-10-18 2016-04-06 Helsinn Healthcare SA Therapeutic combinations of netupitant and palonosetron
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
US20160287524A1 (en) * 2013-03-19 2016-10-06 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015099381A1 (ko) * 2013-12-23 2015-07-02 주식회사 삼양바이오팜 팔로노세트론을 함유하는 약학 조성물
DK3169315T3 (da) 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
WO2016064873A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法
EP4385500A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4633608A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron
EP4633612A1 (en) 2022-12-12 2025-10-22 Alfred E. Tiefenbacher (GmbH & Co. KG) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) 2022-12-12 2024-06-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Antioxidant-free fixed dose combination of netupitant and palonosetron

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
EP0200444B1 (en) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazole-carboxamide having 5-ht antagonist activity
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
NZ236225A (en) * 1989-11-28 1992-09-25 Syntex Inc Azabicyclic-substituted isoquinoline derivatives, intermediates and pharmaceutical compositions
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
AU2003302072A1 (en) * 2002-11-15 2004-06-15 Helsinn Healthcare Sa Palonosetron for the treatment of chemotherapy-induced emesis
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
AU2007308378B2 (en) 2013-02-21
NO342353B1 (no) 2018-05-07
EP1940366B1 (en) 2009-04-08
ZA200902773B (en) 2010-03-31
HN2009000785A (es) 2011-10-14
HRP20090341T1 (hr) 2009-07-31
WO2008049552A1 (en) 2008-05-02
GT200900096A (es) 2011-08-29
HK1117769A1 (en) 2009-01-23
NO20091945L (no) 2009-05-25
CN101573106A (zh) 2009-11-04
JP5144527B2 (ja) 2013-02-13
IL198225A (en) 2013-03-24
CN101573106B (zh) 2013-07-24
CA2666512C (en) 2014-05-27
DE602007000856D1 (de) 2009-05-20
AR063362A1 (es) 2009-01-21
PT1940366E (pt) 2009-06-17
SI1940366T1 (sl) 2009-08-31
ME01949B (me) 2010-08-31
RS50842B (sr) 2010-08-31
EA016455B1 (ru) 2012-05-30
TW200827355A (en) 2008-07-01
KR101441459B1 (ko) 2014-09-18
DK1940366T3 (da) 2009-06-29
CY1109914T1 (el) 2014-09-10
TWI367212B (en) 2012-07-01
US20170035748A1 (en) 2017-02-09
EP1940366A1 (en) 2008-07-09
NZ576237A (en) 2011-12-22
CA2666512A1 (en) 2008-05-02
PL1940366T3 (pl) 2009-09-30
CO6160289A2 (es) 2010-05-20
IL198225A0 (en) 2009-12-24
BRPI0718497B1 (pt) 2024-02-06
UA97653C2 (ru) 2012-03-12
CL2007003055A1 (es) 2008-03-24
EP1940366B9 (en) 2009-12-02
EA200970396A1 (ru) 2009-10-30
ES2325339T3 (es) 2009-09-01
JP2009507933A (ja) 2009-02-26
AU2007308378A1 (en) 2008-05-02
SV2009003238A (es) 2009-11-09
BRPI0718497A2 (pt) 2014-07-08
CR10728A (es) 2009-07-23
KR20090073234A (ko) 2009-07-02
US20080152704A1 (en) 2008-06-26
ATE427742T1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
UA97653C2 (ru) Мягкие капсулы, содержащие палоносетрона гидрохлорид, которые имеют улучшенную стабильность и биологическую доступность
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
IL208832A (en) 3-Aminocarbazole Compound, Pharmaceutical Preparations Containing Them, Methods of Preparation and Use for Drug Preparation
SI2046298T1 (sl) Farmacevtska odmerna oblika, ki vsebuje farmacevtsko sprejemljiv solubilizirni sestavek
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
PT2120878E (pt) Forma farmacêutica contendo duas ou mais substancias ativas em diferentes formas físicas
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
WO2009031606A1 (ja) 関節炎治療及び予防剤
IL212880A0 (en) Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP1804832A4 (en) METHOD AND COMPOSITIONS FOR THE NADLESS DELIVERY OF MACROMOLECULES
ZA200908928B (en) Formulations for the oral administration of therapeutic agents and related methods
WO2011072069A3 (en) Gastric retentive pharmaceutical compositions for extended release of polypeptides
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
WO2005076829A3 (en) Stable loratadine spill resistant formulation
TW200800977A (en) A new salt
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
WO2011161223A3 (en) Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
WO2008010008A3 (en) Cardiovascular combinations using rennin-angiotensin inhibitors
WO2008024846A3 (en) Brimonidine and timolol compositions
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
EP1994003A4 (en) PIPERIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEY
TW200833375A (en) Pharmaceutical compositions
TN2011000588A1 (en) Novel pharmaceutically acceptable salts of 4-(1h-imidazol-4-ylmethyl) pyridine and their therapeutical uses

Legal Events

Date Code Title Description
FG Grant or registration